🔗 Share this article

Given that the US undertakes sweeping revisions to its vaccination schedules, a particular individual has emerged unexpectedly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about coronavirus shots throughout the global health crisis and has zeroed in on alleged fatalities following COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Public health authorities were set to reveal radical changes to the pediatric vaccine schedule earlier this month, bringing the US with the Danish national calendar, according to reports – a major change that would put the US out of alignment with many the global community with little proof for improved outcomes. The planned update has been pushed back until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to speak at the event. She was recently named acting director of the FDA’s CDER, the fifth individual to run the center this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US to become more like the Danish model, a society with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

To date public appearances, she has kept her attention on immunizations – typically the domain of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Questions Over Qualifications

Høeg has no apparent track record in drug development, approval processes or management, which has been typical for former directors of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for running the CDER, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She lacks background in industry regulation.”

Previous directors of the center would “be deeply familiar with legal statutes and the science of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”

The drug center has an vast range of responsibilities at the agency, she emphasized.

“The public just pays attention on the new drug program, but the generic drug division clears a multitude of generic drugs. There’s a biologic copycat branch, OTC medication office and so forth, and each of these have to be supervised,” Woodcock explained. “The area you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a significant leadership element to the position, which supervises in excess of 5,000 employees. “It’s a enormous management job, if you do it right,” she added.

Official Statement and Controversial Policies

In response to questions about Høeg’s qualifications and whether this assignment represents greater collaboration among regulatory chiefs on immunizations, a spokesperson said that the “questions stem from inaccurate assumptions”.

“Her resume aligns with the responsibilities of her job,” the official said, pointing to the time Høeg spent advising the agency head on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched priority voucher program, a disputed one-day drug-approval program that apparently concerned her preceding directors. “By what process are these medications being picked for this voucher program? Who is making the calls?” Dr. Howard asked. “There’s a lot of secrecy occurring at the regulatory body right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of all drugs, except for shots.”

Established History on Immunizations

Regarding vaccines, Høeg has a more established, if troubling, track record, critics observe. She authored a research paper using unverified crowd-sourced reports to determine the rate of myocarditis following Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the incoming federal leadership included changing rules for recently developed shots and ending “optional” immunizations, she said following the vote on a online show. At the FDA, Høeg has reportedly suggested excluding adolescent males from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her conclusions and works backwards to retrofit the evidence in a extremely deceptive, fraudulent manner,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|